JP Morgan Chase
NVIV

JP Morgan Chase’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

JP Morgan Chase’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed – – 7564
2022
Q4 		$0 Buy
+1
New +$3 ﹤0.01% 7403
2020
Q1 		– Hold
0
– – – 5989
2019
Q4 		– Hold
0
– – – 6111
2019
Q3 		– Hold
0
– – – 6153
2019
Q2 		– Hold
0
– – – 6198
2019
Q1 		– Sell
-3
Closed -$3.48K – 6278
2018
Q4 		$4K Buy
+3
New +$4.35K ﹤0.01% 5564
2018
Q3 		– Hold
0
– – – 5990
2018
Q2 		– Hold
0
– – – 5870
2018
Q1 		– Hold
0
– – – 5779

Other funds holding NVIV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

JP Morgan Chase's NVIV Position: Q1 2023 in Review

JP Morgan Chase sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2023, closing a stake of 1 share.

JP Morgan Chase first reported a position in NVIV in Q4 2018 and held it in 2 quarters. The position peaked at $4K in Q4 2018. 20 funds tracked by Wall St. Rank hold NVIV as of Q1 2023.

  • JP Morgan Chase reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1 InVivo Therapeutics Holdings Corp share in Q1 2023.
  • JP Morgan Chase first reported a position in InVivo Therapeutics Holdings Corp in Q4 2018 and held it in 2 quarters.
  • JP Morgan Chase's InVivo Therapeutics Holdings Corp position peaked at $4K in Q4 2018.
  • 20 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2023.

Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.